Clearmind Medicine Inc.
Close on Oct 19, 2026
- Market cap
- $9.49M
- P/E (TTM)
- –
- Dividend yield
- –
About Clearmind Medicine
Pharmaceutical Preparations, SIC 2834
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapies for central nervous system disorders. The company's primary focus is on developing 5-methoxy-2-aminoindane (MEAI), an investigational psychedelic substance intended to treat alcohol use disorder, obesity, metabolic disorders, depression, and addiction. Because its therapeutic candidates are currently undergoing preclinical and clinical development, the company has not commercialized any products or technologies and has not generated revenue from product sales.
Clearmind is incorporated in British Columbia, Canada, and maintains its principal executive offices in Vancouver, British Columbia. The company conducts part of its operations through wholly-owned subsidiaries located in Canada and Israel, specifically Clearmind Labs Corp. in Canada and Clearmindmed Ltd. in Israel. Its common shares trade on The Nasdaq Stock Market LLC.
Summary of the business section of Clearmind Medicine's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Clearmind Medicine Inc.
- Headquarters
- Vancouver, British Columbia, Z4
- Address
- 101-1220 West 6th Avenue V6H1A5
- Phone
- 972-54-5704749
- Website
- clearmindmedicine.com
- Employees
- 2, Oct 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Z4
- Fiscal year ends
- October 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- CMND
- Exchange
- Nasdaq
- IPO date
- Nov 16, 2022
- Shares outstanding
- 0M, Jan 19, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-8 reverse, Oct 5, 2026; 1-for-10 reverse, May 21, 2026; 1-for-40 reverse, Jan 20, 2026; 1-for-40 reverse, Dec 15, 2025; 1-for-30 reverse, Jan 29, 2024; 1-for-30 reverse, Nov 28, 2023
- SEC CIK
- 1892500
- CUSIP
- 185053402
- ISIN
- US1850534025
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Clearmind Medicine's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 16, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 9, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |